Site Search
Search Results
New Paper Finds Barriers to Equitable Discovery and Implementation of Pharmacogenomic Testing in Cancer Care Despite its Power to Improve Patient Outcomes
... February 22, 2024 – A new paper released today in the Journal of Clinical Oncology finds that while incorporating pharmacogenomic (PGx) testing into cancer care can help improve patient outcomes, barriers to PGx testing, discovery, and implementation are impacting its adoption and ... from them.” ACS CAN is working to improve access to PGx testing through its state advocacy work to expand insurance coverage of comprehensive biomarker testing, which includes PGx testing. Biomarker testing is a critical step toward accessing precision medicine, including targeted therapies; however, not all patients who could benefit ...
American Cancer Society and ACS CAN Statement: White House’s Cancer Moonshot National Cancer Plan
... such as the Breast & Cervical Cancer Early Detection Program and accelerate access to innovation through reimbursement strategies ( e.g. biomarker testing). No Untreatable Cancers: Investment in fundamental science produces effective new approaches to precision cancer treatment, particularly ...